Answers are grounded in this paper and cite their sources.
Given the increasing need for lung transplants among older patients with a history of cancer, this study analyzed database registry to assess outcomes for BLT recipients with Pre-TM. This study evaluated the United Network for Organ Sharing (UNOS) registry for adult BLT performed between 2005 and 2023. Patients with a history of previous or multi-organ transplants, and those with donors who had cancer history, were excluded. Propensity-score matching was used to compare patients with or without Pre-TM. Overall and Post-TM-free survival were analyzed. Among the 23,291 recipients of BLT, 8.0%(1,870) had Pre-TM. Compared to those without Pre-TM, patients with Pre-TM had worse overall (hazard ratio[HR] 1.20, 95% confidence interval[CI] 1.12-1.29, p<0.001) and Post-TM-free survival (HR 1.32, 95% CI 1.24-1.41, p<0.001). However, after adjusting for age, sex, and race through propensity-score matching, the survival difference between the groups became non-significant (HR 1.05, 95% CI 0.97-1.13, p=0.229). While the Pre-TM group still had worse Post-TM-free survival, this difference diminished after excluding cutaneous Post-TM (HR 1.06, 95% CI 0.99-1.15, p=0.116). Additionally, the recurrence rate of Pre-TM after transplant wasn't higher than de novo cancers in patients without Pre-TM. Patients with Pre-TM had similar overall survival rates after BLT as those without Pre-TM. Importantly, there was no increased risk of the primary Pre-TM type recurring post-transplant compared to patients without Pre-TM. If patients with PreTM are free from recurrence or metastasis for a significant amount of time, there could be some who can benefit from BLT. Further data regarding timeline between PreTM and BLT would be necessary to draw conclusion in this issue.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: